GGC Medicines


Adult Therapeutics Handbook

Conversion from Warfarin to DOAC (COVID-19)

Appropriate and Safe Conversion from Warfarin to a DOAC during the COVID-19 Pandemic

Introduction

Any patient who is admitted to hospital during the COVID-19 (COVID) pandemic and is taking warfarin (or any other coumarin anticoagulant e.g. phenindione, acenocoumarol) should be considered for switching to a direct oral anticoagulant (DOAC), to avoid the need for ongoing monitoring in hospital and community-based clinics.

Suitable patients for switching from warfarin to a DOAC

Suitable patients for switching from warfarin (or any other coumarin anticoagulant e.g. phenindione, acenocoumarol) to a DOAC (e.g. apixaban, edoxaban) must meet both of the following criteria:

  • The patient has an indication for anticoagulation with a DOAC.
  • The patient has no contraindications to receiving a DOAC.

Indications for which a DOAC can be used

Situations when patients should NOT be switched from warfarin

  • INR target >2.5
  • Pregnant or breastfeeding women
  • Creatinine clearance (CrCl) <15ml/minute 
  • Patients with venous thrombosis and active cancer (when low molecular weight heparin is the preferred anticoagulant)
  • Mechanical heart valves
  • Severe mitral stenosis
  • Liver disease associated with cirrhosis and/or coagulopathy
  • Clear indication for choice of warfarin e.g. recent significant bleed
  • Triple positive antiphospholipid syndrome with previous venous thrombosis i.e. lupus anticoagulant (LA) + anticardiolipin (ACL) + anti beta 2 glycoprotein 1 (B2-GP1). If a patient is LA and ACL positive, but anti B2-GP1 has not been measured, they should be considered triple positive.
  • Patients previously switched from a DOAC to warfarin (or any other coumarin anticoagulant)
  • Patients >120kg or BMI >40
  • Concurrent use of specific medications (see below)

Concurrent Medicines

If switching to apixaban, concurrent use of the following should be avoided:

  • Triazole and imidazole antifungals (except fluconazole)
  • Strong CYP3A4 and P-gp inducers, e.g. ciclosporin, dronedarone, erythromycin, ketoconazole or protease inhibitors

 

If switching to edoxaban:

  • Use with caution and reduce dose to edoxaban oral 30 mg once daily with the following concurrent medicines:
    • Ciclosporin, dronedarone, erythromycin or ketoconazole

The above highlighted interactions should not be considered to be an exhaustive list. Further information regarding interactions is available in the BNF and relevant SPC available from https://www.medicines.org.uk/emc/

Choice of DOAC and process of switching

Non-valvular atrial fibrillation:

Refer to Persistent Atrial Fibrillation guideline for guidance on edoxaban dosing and dose adjustment.

  • Switching from warfarin to edoxaban: discontinue warfarin and start edoxaban when INR is ≤2.5.

Venous thrombosis (first or recurrent event):

Refer to Diagnosis and Treatment of Venous Thromboembolism guideline for full information.

Please note: The following dosing guidance is only applicable to patients who have already been receiving warfarin for their venous thromboembolism. For guidance on new initiations, see the Diagnosis and Treatment of Venous Thromboembolism guideline.

  • If the patient is ≤3 months post-thrombosis, discontinue warfarin and start apixaban oral 5mg twice daily when INR is <2.
  • If >3 months post-thrombosis, discontinue warfarin and start apixaban oral 2.5mg twice daily when INR is <2.

Use apixaban with caution if CrCl 15-29 mL/minute. 

Further advice

For further information / advice regarding the process of converting patients from warfarin to a DOAC, please contact the Glasgow and Clyde Anticoagulation Service (GCAS) - see Appendix 6 for contact details.

If you have any questions regarding the appropriateness of a DOAC for an individual patient, please contact a haematologist - see Appendix 6 for contact details.

 

Content updated May 2020

Page last updated: June 2020